Treg cell therapy to lower anti-rejection meds after kidney transplant
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and getting a kidney from a living donor.
- Your blood type is compatible with your donor's (your transplant team will check this).
- You have never had an organ transplant before.
- You are willing to use effective birth control if you or your partner could become pregnant.
- You do not have serious health issues like active infections, severe heart disease, or recent cancer (within 3 years).
- You do not have a known allergy to certain transplant medicines (like thymoglobulin or tacrolimus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study looks at a new blood test to help monitor the health of your transplanted kidney and check for early signs of rejection. The test will be done as part of your usual care after a kidney transplant.
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.